SAIC Motor’s Hengxu Capital helped allosteric drug developer Nutshell Therapeutics close a $40m round while cancer therapy developer Impact Therapeutics secured series D1 funding.

Funding

China-based allosteric drug developer Nutshell Therapeutics has completed a $40m series A-plus round today featuring carmaker SAIC Motor’s Hengxu Capital fund-of-funds vehicle, DealStreetAsia reported today. Genesis Capital led the round, which included Source Code Capital, Kunlun Capital, Matrix Partners China and Northern Light Venture Capital.

China-headquartered oncology therapy developer Impact Therapeutics closed a series D1 round of undisclosed size yesterday featuring real estate developer Yuexiu Property; C&D Emerging Capital, a vehicle for supply chain services firm Xiamen C&D; and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn